Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medic
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
07:00am, Thursday, 18'th Sep 2025
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neu
BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)
06:41pm, Wednesday, 10'th Sep 2025
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Discuses on SERENITY At-Home Pivotal Phase 3 Safety Trial Results Conference September 10, 2025 02:00 PM ET Company Participants Vimal Mehta - Founder, CEO, P
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
03:08pm, Wednesday, 10'th Sep 2025
BioXcel Therapeutics, Inc. BTAI on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects an
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Thursday, 04'th Sep 2025
NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neu
BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment
12:01pm, Wednesday, 27'th Aug 2025
BioXcel Therapeutics Inc. BTAI announced that its SERENITY At-Home Phase 3 trial of BXCL501—its sublingual dexmedetomidine film for acute agitation in bipolar disorder or schizophrenia—met its pri
BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia
BioXcel's agitation drug meets main goal in at-home study
07:29am, Wednesday, 27'th Aug 2025
BioXcel Therapeutics said on Wednesday its experimental agitation drug met the main goal of a late-stage study testing it in patients with bipolar disorder or schizophrenia for at-home use.
BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia
NEW HAVEN, Conn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasd
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
07:00am, Wednesday, 13'th Aug 2025
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates
04:01pm, Tuesday, 12'th Aug 2025
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.45 per share versus the Zacks Consensus Estimate of a loss of $2.3. This compares to a loss of $3.36 per share a year ago.
